Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Policy & Acquisitions

Mergers & Acquisitions

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Mergers & Acquisitions

214 stories · every one Fact-Checked
533Mergers & AcquisitionsTakeda Partners With Insilico Medicine in AI Drug Discovery Deal Worth Up to $600 MillionInsilico Medicine and Takeda have entered a strategic collaboration to accelerate AI-driven drug discovery. Leveraging Insilico’s Pharma.AI platform and Takeda’s global development expertise, the alliance spans multiple therapeutic…3 Jul 2026 · 3 min read
Fact-Checked
thymusMergers & AcquisitionsUnited Therapeutics Acquires Thymmune to Expand T-Cell Regeneration ResearchUnited Therapeutics is strengthening its regenerative medicine strategy with the acquisition of Thymmune Therapeutics.2 Jul 2026 · 3 min read
Fact-Checked
memoMergers & AcquisitionsIpsen Acquires Memo Therapeutics, Adds Potravitug to Rare Disease PipelineIpsen has signed a definitive agreement to acquire Memo Therapeutics AG, adding potravitug, a first‑in‑class antibody in Phase II for BK polyomavirus‑associated nephropathy.1 Jul 2026 · 3 min read
Fact-Checked
Close-up of two businessmen shaking hands, symbolizing agreement and partnership.Mergers & AcquisitionsInnovent Secures Exclusive China Rights to Lilly’s VerzeniosInnovent Biologics will commercialize Lilly’s Verzenios in mainland China under a new agreement, broadening patient access to the CDK4/6 inhibitor across early and advanced HR+/HER2‑ breast cancer indications…30 Jun 2026 · 3 min read
Fact-Checked
Ipsen-master-logo_RGB_350x260pixMergers & AcquisitionsIpsen to Acquire Kartos Therapeutics in Up to $1.75B Deal, Adds Myelofibrosis Drug NavtemadlinIpsen is acquiring Kartos Therapeutics in a deal worth up to $1.75B, gaining navtemadlin, an oral MDM2 inhibitor in Phase III development for myelofibrosis patients with suboptimal response…29 Jun 2026 · 3 min read
Fact-Checked
A woman scientist using a microscope in a laboratory setting.Mergers & AcquisitionsElixirgen and Nippon Shinyaku Partner to Advance Full-Length Dystrophin mRNA Therapy EXG-7001 for Duchenne Muscular DystrophyElixirgen Therapeutics has entered into an option agreement with Nippon Shinyaku to develop EXG-7001, an investigational full-length dystrophin mRNA therapy for Duchenne muscular dystrophy (DMD).27 Jun 2026 · 3 min read
Fact-Checked
11148LOW_VIBRANTCYANLOGOOU_11zonMergers & AcquisitionsMerck KGaA to Acquire Bio-Techne for $11.3 Billion to Expand Life Science PortfolioMerck KGaA, Darmstadt, Germany will acquire Bio-Techne in an all-cash deal valued at US$11.3 billion (€9.9 billion), expanding its life science portfolio across research, bioprocessing, and advanced therapeutics.…26 Jun 2026 · 3 min read
Fact-Checked
Gemini_Generated_Image_sovzkysovzkysovzMergers & AcquisitionsNovartis Partners With Antares in Up to $1.9 Billion Oncology Drug DealAntares Therapeutics has partnered with Novartis in a multi-target oncology collaboration to discover and develop small molecule therapies for historically undruggable cancer targets.25 Jun 2026 · 3 min read
Fact-Checked
Gemini_Generated_Image_ty82ljty82ljty82Mergers & AcquisitionsIonis Partners with Recordati to Commercialize Zilganersen for Alexander Disease Outside the U.S.Ionis Pharmaceuticals has partnered with Recordati to develop and commercialize investigational RNA therapy zilganersen outside the United States, while retaining U.S. rights.25 Jun 2026 · 3 min read
Fact-Checked
Gemini_Generated_Image_hbcgk5hbcgk5hbcgMergers & AcquisitionsEli Lilly Expands Abbisko Alliance in Up to $1.9 Billion Multi-Target Drug Discovery DealEli Lilly and Abbisko Therapeutics have signed a new multi-target drug discovery and licensing agreement worth up to US$1.9 billion in potential milestone payments.25 Jun 2026 · 3 min read
Fact-Checked
Scientists in a laboratory analyzing samples with advanced equipment and protective gear.Mergers & AcquisitionsNuvectis Adds Late-Stage NXP100 and NXP200 in Haisco Licensing DealNuvectis Pharma has licensed ex-China rights to NXP100 and NXP200 from Haisco, expanding into complement-mediated diseases and strengthening its oncology pipeline with two clinical-stage assets advancing in China.24 Jun 2026 · 3 min read
Fact-Checked
143120Mergers & AcquisitionsInsilico and SK Biopharmaceuticals Pursue New Neuroimmune Treatments Using AIInsilico Medicine and SK Biopharmaceuticals unveiled a $2.5B collaboration at BIO 2026 to discover therapies for neuroimmune CNS disorders.23 Jun 2026 · 3 min read
Fact-Checked
Page 9 of 18